Such strategy has been employed by the studies of Sheldrake et al., Travica et al., Pors et al., Meng et al., Sutherland et al. and Androutsopoulos et al., for the development of novel selective CYP1-targeted cancer therapeutics [19-21,43-45]. Here, CYP1A1 is linked to cancer.